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Summary 
Objectives: To report on the design, significance and potential impacts of the first 
documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an 
aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative 
element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study 
(KADSS) is a 3-week placebo-controlled, double-blind, crossover trial involving 60 adult 
participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms. 
Aims: The aims of KADSS are: 1) To determine whether an aqueous standardised extract of 
kava is effective for the treatment of anxiety; 2) To assess the effects of kava on differing 
levels of depression; and 3) To explore participants’ experience of taking kava via qualitative 
research. The study also provides preliminary assessment of the safety of an aqueous extract 
of kava in humans.   
Conclusion: If results reveal that the aqueous kava preparation exerts significant anxiolytic 
effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and 
effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. 
This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of 
anxiety disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
No substantial advances in pharmaceutical treatments of anxiety disorders have occurred in 
the last two decades.1 Orthodox medical treatments of anxiety disorders include synthetic 
anxiolytics (e.g. benzodiazepines, β-blockers), antidepressants and psychological 
interventions (e.g. cognitive behavioural therapy).2 As synthetic pharmacotherapies have 
significant potential side effects,1 and in the case of benzodiazepines, present issues of 
dependence and withdrawal, further research into safe and effective anxiolytics is needed.  
Piper methysticum (kava) has good evidence as an effective anxiolytic agent,3, 4 and 
has demonstrated equivalent efficacy to buspirone or opipramol in treating generalised 
anxiety disorder.5 Nevertheless, kava was withdrawn from European and UK markets in 
2002 due to concerns over reported hepatotoxicity.6, 7 In many of these case reports it was 
unclear whether kava was responsible for the hepatotoxicity, particularly in those involving 
concomitant ingestion of other compounds with potential hepatotoxicity (e.g. other 
medications and/or alcohol).6  Factors potentially responsible for possible hepatotoxic effects 
include hepatic insufficiency to metabolise kavalactones, preparations low in glutathione, use 
of aerial parts or root peelings (higher in alkaloids) in preparations, or the use of acetonic or 
ethanolic kava extracts.7-9 As the widespread traditional use of kava beverages in the South 
Pacific is not typically associated with liver toxicity, it is possible that the method of 
preparation, plant part used, and kava cultivar, is responsible for any adverse hepatic effects 
that may have occurred.10 Research into kava preparations that are reflective of traditional 
usage is urgently needed. In a World Health Organisation commissioned report assessing the 
risk of kava products, recommendation 2.1.3 states that “products from water based 
suspensions and further synthetic preparations should be developed and tested in clinical 
trials and consideration given to using these in preference to acetonic and ethanolic 
extracts.”11 To our knowledge, there are no published studies examining the efficacy of a 
standardised aqueous extract of the peeled root of Piper methysticum. As current synthetic 
pharmacological treatment of anxiety disorders involving benzodiazepines has significant 
potential health risks and clear dependency issues,1, 12 a standardised aqueous kava extract 
remains a viable potential therapeutic option. 
The potential impact of a successful human clinical trial using an aqueous extract is 
two-fold. Firstly, the impact of European and UK withdrawal of kava was devastating to the 
South Pacific economies.10 Evidence of a safe and efficacious non-acetonic/ethanolic extract 
(aqueous extract) of kava may begin in the process to encourage these governments to re-
introduce kava to the markets, thereby benefiting South Pacific economies and enhancing 
stability in the region. Secondly, as evidence-based pharmacotherapeutic options are 
currently limited, and present with potentially significant issues of adverse effects and 
dependence, a safe and effective kava preparation may provide an additional beneficial 
therapeutic option. It is well established that depressed patients with comorbid anxiety 
disorders have a poorer prognosis, and exert greater societal demands in terms of increased 
health care costs and lower work productivity.2, 13, 14 A safe and effective aqueous extract of 
kava may provide significant assistance in reducing the socioeconomic burden of anxiety 
(with or without co-occuring depression), may improve the quality of life of anxiety 
sufferers, and potentially benefit the people of the South Pacific.  
 
Design of the trial 
To establish efficacy and safety of an aqueous extract of kava, and to explore novel areas 
of research, we formulated the following trial design. The Kava Anxiety Depression 
Spectrum Study (KADSS) is a 3-week placebo-controlled, double-blind, crossover trial. 
Sixty adult participants (18-65) with elevated stable generalised anxiety and varying 
levels of depressive symptoms are currently being recruited. Eligible participants undergo 
a 1-week placebo run-in period before randomisation. Placebo responders will be 
excluded (i.e. participants obtaining at least a 50% reduction in anxiety scores). 
Outcomes are measured by the Beck Anxiety Inventory,15 Hamilton Anxiety Scale,16 and 
Montgomery-Asberg Depression Scale.17 Qualitative semi-structured questionnaires are 
conducted during the controlled phases at weeks 2 and 3. Five tablets per day of kava 
(2.66g each standardised for 50mg of kavalactones) are prescribed (2 tablets twice a day 
and one tablet in the evening providing a total of 250mg kavalactones, the maximum 
dose approved in Australia). The kavalactone profile of the tablets used in the study 
should be consistent with the profile of traditional aqueous kava beverages. This will be 
assessed by an independant analysis of the constituents in the tablets. The kava tablets are 
supplied by MediHerb Pty Ltd. Although no 'washout phase' is adopted in the crossover 
study, pharmacokinetic clearance of the kavalactones should be complete after 
approximately two days in the kava-placebo group.18 While there may be an initial 
carryover effect, this should be absent by the time of final assessment. 
The strengths of using a ‘mixed methods’ approach in KADSS, is that quantitative 
outcomes may determine efficacy, while qualitative research will provide an added in-
depth, rich examination of the participants experience of taking kava, exploring 
previously undocumented effects, potential adverse reactions, and any positive 
therapeutic occurrences. This is important if we are to accommodate and consider 
outcomes, efficacy and future use/behaviour. While randomised controlled trials remain 
the gold standard for providing evidence of efficacy for therapeutic interventions, 
qualitative research provides valuable insight to phenomena that quantitative research and 
data cannot adequately depict.19, 20 To date we are unaware of any kava RCTs employing 
a qualitative component.        
 
Aims and Predictions of the Study 
The aims of KADSS are: 1) To determine whether an aqueous standardised extract of 
kava is effective for the treatment of anxiety; 2) To assess the effects of kava on differing 
levels of depression; and 3) To explore participants’ experience of taking kava via 
qualitative research. The study also provides assessment of the safety of an aqueous 
extract of kava in humans. Our prediction is that if the kava preparation exerts a 
significant anxiolytic effect, the efficacy may be reduced in participants with higher 
levels of depression. In accordance with our previous study using an aqueous extract of 
kava (prescribed in a combination with St John’s wort),21 and in vivo results by Singh and 
Devkota,22 we expect the extract to be safe. It should however be noted that RCT sample 
sizes are too small to detect any potential rare occurrence of hepatotoxicity. Regardless, 
the 'heterogeneous' sample used in the study is representative of ‘real world’ use, and this 
is likely to provide a high external validity of findings.  
 
Conclusion 
KADSS will critically examine whether an aqueous extract of kava is effective in the 
treatment of anxiety, and will provide preliminary assessment of its clinical safety. If the 
outcome of KADSS reveals a clinically significant anxiolytic effect, the study will advance 
the case for the re-introduction of kava to the UK and European markets. KADSS will also 
assess whether the efficacy of kava is altered by depression level. To our knowledge clinical 
trials of kava using depression outcomes have not been conducted. It is currently not 
definitively known whether kava has thymoleptic or depressogenic effects, and whether it 
can be clinically recommended or contraindicated in unipolar or bipolar depression, or in 
comorbid presentations of depression with other psychiatric disorders. If we can determine 
this, the results will impact clinical recommendations of kava use (i.e. whether it should be 
contraindicated or recommended in depressive presentations). Qualitative assessments are 
expected to identify previously known, and possibly unknown, effects of kava. This appears 
to be the first documented clinical trial using an aqueous extract of kava in humans; and the 
first which systematically assesses the efficacy of kava versus placebo in a sample with 
varying levels of depression.  
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